SFM
KNTE

Sphera Funds Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Sphera Funds Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-91,673
Closed -$1.16M – 92
2022
Q2 		$1.16M Buy
+91,673
New +$853K 0.12% 49

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Sphera Funds Management's KNTE Position: Q3 2022 in Review

Sphera Funds Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2022, closing a stake of 91,673 shares — an estimated $1.16M sold.

Sphera Funds Management first reported a position in KNTE in Q2 2022 and held it in 1 quarter. The position peaked at $1.16M in Q2 2022. 84 funds tracked by Wall St. Rank hold KNTE as of Q3 2022.

  • Sphera Funds Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Sphera Funds Management sold 91,673 Kinnate Biopharma Inc. Common Stock shares in Q3 2022, an estimated $1.16M.
  • Sphera Funds Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Sphera Funds Management's Kinnate Biopharma Inc. Common Stock position peaked at $1.16M in Q2 2022.
  • 84 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2022.

Based on Sphera Funds Management's 13F filing for Q3 2022, filed 14 Nov 2022.